
Entrada Therapeutics, Inc.: shareholders and insiders
Price
$5.00
November 16, 2026Market cap $191M
What Ploutos Investor adds for Entrada Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Sep 9, 2026, from their own Form 4 filings.
Bought on the market
$291.1K
2 people
Sold on the market
$12M
7 people
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan11%
- The rest89%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $29.3K by 1 person·sold $6.7M by 9 people
- 2025: bought $261.8K by 1 person, sold $88.9K by 1 person
- 2026: bought $29.3K by 1 person, sold $6.7M by 9 people
- Sep 9, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 9, 2026MPM BioVentures 2014, L.P.Kind
- Sep 8, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 8, 2026MPM BioVentures 2014, L.P.Kind
- Sep 4, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 4, 2026MPM BioVentures 2014, L.P.Kind
- Sep 3, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 3, 2026MPM BioVentures 2014, L.P.Kind
- Sep 2, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 2, 2026MPM BioVentures 2014, L.P.Kind
- Sep 2, 2026Dipal DoshiCEOKind
- Sep 2, 2026Nathan J DowdenPresident & COOKind
- Sep 2, 2026Natarajan SethuramanPresident, Research & Develop.Kind
- Sep 2, 2026Kory James WentworthChief Financial OfficerKind
- Sep 1, 2026Mpm Bioventures 2018, L.p.Kind
- Sep 1, 2026MPM BioVentures 2014, L.P.Kind
- Aug 31, 2026Mpm Bioventures 2018, L.p.Kind
- Aug 31, 2026MPM BioVentures 2014, L.P.Kind
- Aug 28, 2026Mpm Bioventures 2018, L.p.Kind
- Aug 28, 2026MPM BioVentures 2014, L.P.Kind
- Aug 27, 2026Mpm Bioventures 2018, L.p.Kind
- Aug 27, 2026MPM BioVentures 2014, L.P.Kind
- Aug 26, 2026MPM BioVentures 2014, L.P.Kind
- Aug 26, 2026Mpm Bioventures 2018, L.p.Kind
- Aug 25, 2026MPM BioVentures 2014, L.P.Kind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Mpm Bioventures 2018, L.p. | 28.8K | $7.13 | $205.6K | Form 4 | |
| Sep 9, 2026 | MPM BioVentures 2014, L.P. | 28.8K | $7.13 | $205.6K | Form 4 | |
| Sep 8, 2026 | Mpm Bioventures 2018, L.p. | 192.5K | $7.41 | $1.4M | Form 4 | |
| Sep 8, 2026 | MPM BioVentures 2014, L.P. | 192.5K | $7.41 | $1.4M | Form 4 | |
| Sep 4, 2026 | Mpm Bioventures 2018, L.p. | 38.5K | $7.11 | $273.7K | Form 4 | |
| Sep 4, 2026 | MPM BioVentures 2014, L.P. | 38.5K | $7.11 | $273.7K | Form 4 | |
| Sep 3, 2026 | Mpm Bioventures 2018, L.p. | 32.3K | $7.17 | $231.3K | Form 4 | |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. | 32.3K | $7.17 | $231.3K | Form 4 | |
| Sep 2, 2026 | Mpm Bioventures 2018, L.p. | 25.1K | $7.19 | $180.7K | Form 4 | |
| Sep 2, 2026 | MPM BioVentures 2014, L.P. | 25.1K | $7.19 | $180.7K | Form 4 | |
| Sep 2, 2026 | Dipal DoshiCEO | 8,724 | $7.14 | $62.3K | Form 4 | |
| Sep 2, 2026 | Nathan J DowdenPresident & COO | 2,528 | $7.14 | $18.1K | Form 4 | |
| Sep 2, 2026 | Natarajan SethuramanPresident, Research & Develop. | 2,079 | $7.14 | $14.9K | Form 4 | |
| Sep 2, 2026 | Kory James WentworthChief Financial Officer | 1,733 | $7.14 | $12.4K | Form 4 | |
| Sep 1, 2026 | Mpm Bioventures 2018, L.p. | 29.1K | $7.06 | $205.4K | Form 4 | |
| Sep 1, 2026 | MPM BioVentures 2014, L.P. | 29.1K | $7.06 | $205.4K | Form 4 | |
| Aug 31, 2026 | Mpm Bioventures 2018, L.p. | 44.3K | $6.99 | $309.4K | Form 4 | |
| Aug 31, 2026 | MPM BioVentures 2014, L.P. | 44.3K | $6.99 | $309.4K | Form 4 | |
| Aug 28, 2026 | Mpm Bioventures 2018, L.p. | 3,733 | $7.01 | $26.2K | Form 4 | |
| Aug 28, 2026 | MPM BioVentures 2014, L.P. | 3,733 | $7.01 | $26.2K | Form 4 | |
| Aug 27, 2026 | Mpm Bioventures 2018, L.p. | 38.9K | $7.20 | $280.2K | Form 4 | |
| Aug 27, 2026 | MPM BioVentures 2014, L.P. | 38.9K | $7.20 | $280.2K | Form 4 | |
| Aug 26, 2026 | MPM BioVentures 2014, L.P. | 14.6K | $7.06 | $102.9K | Form 4 | |
| Aug 26, 2026 | Mpm Bioventures 2018, L.p. | 14.6K | $7.06 | $102.9K | Form 4 | |
| Aug 25, 2026 | MPM BioVentures 2014, L.P. | 26.5K | $7.54 | $200.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 12, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by TRDA's officers and directors from 2021 up to November 16, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- 5AM Ventures V, L.P.with 6 more personsShare of class10.8%
- MPM BioVentures 2014, L.P.with 12 more personsShare of class9.90%
- Roche Finance Ltdwith 1 more personShare of class6.90%
- BlackRock, Inc.Share of class5.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P.with 6 more persons | 10.8% | 4.12M | Nov 18, 2025 | 13D/A | |
| MPM BioVentures 2014, L.P.with 12 more persons | 9.90% | 3.89M | Sep 10, 2026 | 13D/A | |
| Roche Finance Ltdwith 1 more person | 6.90% | 2.57M | Feb 14, 2025 | 13G/A | |
| BlackRock, Inc. | 5.30% | 1.97M | Feb 4, 2025 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+83%
- Millennium Mgmt (Englander)In the quarter+47%
- D.E. ShawIn the quarter-59%
- Renaissance TechnologiesIn the quarter+4.3%
- AQR CapitalIn the quarter+780%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 28.5K | $200.0K | 0.00% | |
| Citadel Advisors (Griffin) | 394.3K | +83% | $2.9M | 0.00% |
| Millennium Mgmt (Englander) | 764.0K | +47% | $5.6M | 0.00% |
| D.E. Shaw | 32.4K | -59% | $200.0K | 0.00% |
| Renaissance Technologies | 199.2K | +4.3% | $1.3M | 0.00% |
| AQR Capital | 699.5K | +780% | $5.1M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.55% of its shares outstanding were held short, +9.4% since the report before.
- Shares held short
- 3.27M
- 8.55%
- Since the report before2.99M on Sep 30, 2026
- +9.4%
- 8.6
- 380.6K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 86%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.72M
- Nov 15, 2023: Shares held short 1.66M
- Nov 30, 2023: Shares held short 1.78M
- Dec 15, 2023: Shares held short 1.79M
- Dec 29, 2023: Shares held short 1.84M
- Jan 12, 2024: Shares held short 1.82M
- Jan 31, 2024: Shares held short 1.83M
- Feb 15, 2024: Shares held short 1.81M
- Feb 29, 2024: Shares held short 1.81M
- Mar 15, 2024: Shares held short 1.79M
- Mar 28, 2024: Shares held short 1.77M
- Apr 15, 2024: Shares held short 1.75M
- Apr 30, 2024: Shares held short 1.72M
- May 15, 2024: Shares held short 1.66M
- May 31, 2024: Shares held short 1.63M
- Jun 14, 2024: Shares held short 1.67M
- Jun 28, 2024: Shares held short 1.74M
- Jul 15, 2024: Shares held short 1.88M
- Jul 31, 2024: Shares held short 1.96M
- Aug 15, 2024: Shares held short 2.07M
- Aug 30, 2024: Shares held short 2.14M
- Sep 13, 2024: Shares held short 2.17M
- Sep 30, 2024: Shares held short 2.04M
- Oct 15, 2024: Shares held short 1.65M
- Oct 31, 2024: Shares held short 1.66M
- Nov 15, 2024: Shares held short 1.61M
- Nov 29, 2024: Shares held short 1.53M
- Dec 13, 2024: Shares held short 1.64M
- Dec 31, 2024: Shares held short 1.84M
- Jan 15, 2025: Shares held short 1.88M
- Jan 31, 2025: Shares held short 1.68M
- Feb 14, 2025: Shares held short 1.52M
- Feb 28, 2025: Shares held short 1.38M
- Mar 14, 2025: Shares held short 1.23M
- Mar 31, 2025: Shares held short 1.17M
- Apr 15, 2025: Shares held short 1.10M
- Apr 30, 2025: Shares held short 1.06M
- May 15, 2025: Shares held short 1.06M
- May 30, 2025: Shares held short 1.09M
- Jun 13, 2025: Shares held short 1.10M
- Jun 30, 2025: Shares held short 1.25M
- Jul 15, 2025: Shares held short 1.30M
- Jul 31, 2025: Shares held short 1.15M
- Aug 15, 2025: Shares held short 1.07M
- Aug 29, 2025: Shares held short 1.08M
- Sep 15, 2025: Shares held short 1.06M
- Sep 30, 2025: Shares held short 813.4K
- Oct 15, 2025: Shares held short 944.2K
- Oct 31, 2025: Shares held short 893.8K
- Nov 14, 2025: Shares held short 926.5K
- Nov 28, 2025: Shares held short 948.6K
- Dec 15, 2025: Shares held short 898.8K
- Dec 31, 2025: Shares held short 760.3K
- Jan 15, 2026: Shares held short 858.5K
- Jan 30, 2026: Shares held short 896.1K
- Feb 13, 2026: Shares held short 908.9K
- Feb 27, 2026: Shares held short 822.9K
- Mar 13, 2026: Shares held short 924.3K
- Mar 31, 2026: Shares held short 894.2K
- Apr 15, 2026: Shares held short 852.2K
- Apr 30, 2026: Shares held short 998.4K
- May 15, 2026: Shares held short 1.51M
- May 29, 2026: Shares held short 1.73M
- Jun 15, 2026: Shares held short 1.91M
- Jun 30, 2026: Shares held short 2.11M
- Jul 15, 2026: Shares held short 2.23M
- Jul 31, 2026: Shares held short 2.14M
- Aug 14, 2026: Shares held short 2.37M
- Aug 31, 2026: Shares held short 2.35M
- Sep 15, 2026: Shares held short 2.74M
- Sep 30, 2026: Shares held short 2.99M
- Oct 15, 2026: Shares held short 3.27M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading43.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 43.7% of the shares in the reported trades were short sales, against 45.6% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 43.7%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 45.6%
- Change
- -1.9 pts
- Short sales a dayon average, of 221.1K shares
- 96.7K
- More than atof 3,668 US-listed companies, same days
- 29%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 58.8%
- Oct 9, 2026: Short sales 52%
- Oct 12, 2026: Short sales 44.1%
- Oct 13, 2026: Short sales 32.4%
- Oct 14, 2026: Short sales 47%
- Oct 15, 2026: Short sales 63.7%
- Oct 16, 2026: Short sales 38.5%
- Oct 19, 2026: Short sales 39.4%
- Oct 20, 2026: Short sales 47%
- Oct 21, 2026: Short sales 36.9%
- Oct 22, 2026: Short sales 62.2%
- Oct 23, 2026: Short sales 50%
- Oct 26, 2026: Short sales 43.2%
- Oct 27, 2026: Short sales 19.1%
- Oct 28, 2026: Short sales 36.9%
- Oct 29, 2026: Short sales 23.1%
- Oct 30, 2026: Short sales 47.3%
- Nov 2, 2026: Short sales 63.7%
- Nov 3, 2026: Short sales 29.3%
- Nov 4, 2026: Short sales 57.3%
- Nov 5, 2026: Short sales 22.7%
- Nov 6, 2026: Short sales 26.4%
- Nov 9, 2026: Short sales 66.3%
- Nov 10, 2026: Short sales 20.5%
- Nov 11, 2026: Short sales 33%
- Nov 12, 2026: Short sales 46.6%
- Nov 13, 2026: Short sales 57.9%
- Nov 16, 2026: Short sales 61%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Mpm Bioventures 2018, L.p.Directly11.91M
- MPM BioVentures 2014, L.P.Directly11.91M
- Mpm Asset Management Investors Bv2018 LlcTenPercentOwnerDirectly–
- Todd FoleyTenPercentOwnerDirectly–
- Andrew J. SchwabTenPercentOwnerDirectly3.18M
- 5AM Opportunities I, L.P.TenPercentOwnerDirectly3.16M
- MPM BioVentures 2014 (B), L.P.TenPercentOwnerDirectly–
- MPM BioVentures 2014 GP LLCTenPercentOwnerDirectly–
- MPM BioVentures 2018 LLCTenPercentOwnerDirectly–
- Mpm Bioventures 2018 (b), L.p.TenPercentOwnerDirectly–
- MPM BioVentures 2018 GP LLCTenPercentOwnerDirectly–
- 5AM Ventures V, L.P.TenPercentOwnerDirectly3.88M
- Scott M RocklageTenPercentOwnerDirectly2.78M
- Kush ParmarDirectorDirectly–
- Dipal DoshiCEODirectly517.3K
- Felix BakerTenPercentOwnerDirectly–
- Baker Bros. Advisors (GP) LLCTenPercentOwnerDirectly–
- Natarajan SethuramanPresident, Research & Develop.Directly214.2K
- Nathan J DowdenPresident & COODirectly196.1K
- Peter S KimDirectorDirectly117.4K
- Kory James WentworthChief Financial OfficerDirectly117.3K
- Bernhardt G ZeiherDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Mpm Bioventures 2018, L.p. | 11.91M | – | Sep 9, 2026 | Form 4 |
| MPM BioVentures 2014, L.P. | 11.91M | – | Sep 9, 2026 | Form 4 |
| Mpm Asset Management Investors Bv2018 LlcTenPercentOwner | – | 4.38M | Dec 11, 2024 | Form 4 |
| Todd FoleyTenPercentOwner | – | 4.32M | Aug 26, 2026 | Form 4 |
| Andrew J. SchwabTenPercentOwner | 3.18M | 1.10M | Jul 1, 2025 | Form 4 |
| 5AM Opportunities I, L.P.TenPercentOwner | 3.16M | 1.09M | Jul 9, 2025 | Form 4 |
| MPM BioVentures 2014 (B), L.P.TenPercentOwner | – | 4.23M | Aug 31, 2026 | Form 4 |
| MPM BioVentures 2014 GP LLCTenPercentOwner | – | 4.14M | Sep 3, 2026 | Form 4 |
| MPM BioVentures 2018 LLCTenPercentOwner | – | 4.14M | Sep 3, 2026 | Form 4 |
| Mpm Bioventures 2018 (b), L.p.TenPercentOwner | – | 3.89M | Sep 9, 2026 | Form 4 |
| MPM BioVentures 2018 GP LLCTenPercentOwner | – | 3.89M | Sep 9, 2026 | Form 4 |
| 5AM Ventures V, L.P.TenPercentOwner | 3.88M | – | Aug 7, 2026 | Form 4 |
| Scott M RocklageTenPercentOwner | 2.78M | – | Aug 7, 2026 | Form 4 |
| Kush ParmarDirector | – | 2.69M | Aug 10, 2026 | Form 4 |
| Dipal DoshiCEO | 517.3K | – | Sep 2, 2026 | Form 4 |
| Felix BakerTenPercentOwner | – | 380.2K | Nov 20, 2025 | Form 4 |
| Baker Bros. Advisors (GP) LLCTenPercentOwner | – | 378.9K | Nov 12, 2025 | Form 4 |
| Natarajan SethuramanPresident, Research & Develop. | 214.2K | – | Sep 2, 2026 | Form 4 |
| Nathan J DowdenPresident & COO | 196.1K | – | Sep 2, 2026 | Form 4 |
| Peter S KimDirector | 117.4K | – | May 14, 2024 | Form 4 |
| Kory James WentworthChief Financial Officer | 117.3K | – | Sep 2, 2026 | Form 4 |
| Bernhardt G ZeiherDirector | – | 5,000 | May 20, 2026 | Form 4 |
A lower bound: it counts only the 22 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- IBBiShares Biotechnology ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- DFSVDimensional US Small Cap Value ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
- SCHBSchwab U.S. Broad Market ETFWeight in the fund0.00%
12 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 116
- Q4 2025: Managers 113
- Q1 2026: Managers 120
- Q2 2026: Managers 129
Institutional investors by quarter
The fund managers holding TRDA, quarter by quarter, from Q4 2021 to Q2 2025, 15 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 129 managers held 29.45M shares, worth $217M. During the quarter 27 opened a position, 18 closed one, 53 added and 30 trimmed.
The largest holders, Q2 2026
- Baker Bros. AdvisorsIn the quarter
- 5AM Venture ManagementIn the quarter
- BlackRockIn the quarter+9.5%
- MerckIn the quarter
- Vanguard Capital ManagementIn the quarter+1.1%
- Mpm BioimpactIn the quarter
- TCG Crossover ManagementIn the quarter-54%
- Wellington Management GroupIn the quarter-7.8%
- Millennium Mgmt (Englander)In the quarter+47%
- StepStone GroupIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Baker Bros. Advisors | 5.07M | $37M | |
| 5AM Venture Management | 4.06M | $30M | |
| BlackRock | 2.58M | +9.5% | $19M |
| Merck | 1.74M | $13M | |
| Vanguard Capital Management | 1.27M | +1.1% | $9.3M |
| Mpm Bioimpact | 1.25M | $9.2M | |
| TCG Crossover Management | 1.06M | -54% | $7.8M |
| Wellington Management Group | 954.4K | -7.8% | $7.0M |
| Millennium Mgmt (Englander) | 764.0K | +47% | $5.6M |
| StepStone Group | 761.3K | $5.6M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Entrada Therapeutics's filings show?
Who buys and sells is one part of Entrada Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have TRDA's insiders bought or sold?
From Jun 12, 2026 to Sep 9, 2026 Entrada Therapeutics's insiders bought 0 and sold $10M of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold TRDA?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $5.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.